Renato Skerlj, Expansion Therapeutics CEO

Drug­ging RNA was once con­sid­ered im­pos­si­ble. Now Big Phar­ma can't get enough of it

Once con­sid­ered im­pos­si­ble, Big Phar­ma has warmed up to the idea of drug­ging RNA over the last few years, ink­ing plat­form deals with com­pa­nies like Ar­rakis and Sky­hawk. Now, Sanofi and No­var­tis are reach­ing a lit­tle deep­er in­to their wal­lets for one of the ear­li­est play­ers in this are­na.

Ex­pan­sion Ther­a­peu­tics un­veiled an $80 mil­lion Se­ries B round on Wednes­day morn­ing to bring its small mol­e­cule RNA plat­form one step clos­er to the clin­ic. Cor­morant As­set Man­age­ment led the round, while some big name back­ers like No­var­tis’ and Sanofi’s ven­ture arms chipped in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.